These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39687611)

  • 1. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.
    Zhou N; Hua Y; Ge Y; Wang Q; Wang C; He J; Zhao L; Yu S; Yan J; Zhao L; Li L; Bai C
    Front Immunol; 2024; 15():1482005. PubMed ID: 39687611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma.
    Cai H; Chen L; Huang J; Ma H; Zhang S; Zhong K; Yang D; Sun J; Liu H; Song R
    Front Immunol; 2024; 15():1453176. PubMed ID: 39697347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial.
    Zhang PF; Chen Y; Li WK; Luo ZM; Chen J; Qian K; Chen XD; Wang MJ; Liu M
    Front Immunol; 2024; 15():1431957. PubMed ID: 39606219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy.
    Shan J; Liu Z; Chen S; Du C; Li B; Ruan L; Kong M; Wang L; Du M; Shi S; Qiao G; Tian T; Tu Z
    BMC Med; 2024 Jun; 22(1):234. PubMed ID: 38853265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study.
    Yin L; Jiang W; Liu S; Fu Y; Zhou L; Pei X; Ye S; Shen W; Yang H; Shan B
    BMC Med; 2024 Oct; 22(1):496. PubMed ID: 39468597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
    Liu SL; Li XY; Yang JH; Wen DX; Guo SS; Liu LT; Li YF; Luo MJ; Xie SY; Liang YJ; Sun XS; Yang ZC; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Lan KQ; Jia GD; Li R; Zhao C; Xu RH; Chen QY; Tang LQ; Mai HQ
    Lancet Oncol; 2024 Dec; 25(12):1563-1575. PubMed ID: 39522541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma].
    Wang XY; Shen HX; Li RH; Wang JF; Fang M; Tao KY; Jiang YH; Ji YL
    Zhonghua Zhong Liu Za Zhi; 2024 Nov; 46(11):1058-1066. PubMed ID: 39622738
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy.
    Torigoe R; Oshikiri T; Goto H; Koterazawa Y; Sawada R; Ikeda T; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
    Anticancer Res; 2024 Dec; 44(12):5485-5493. PubMed ID: 39626938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial.
    Zeng Y; Li J; Ye J; Han G; Luo W; Wu C; Qin S; Gu W; Zhao S; Zhao Y; Xia B; Zhu Z; Du X; Liu Y; Liu J; Li H; Wang J; Guo J; Yu W; Zhang Q; Wang C; Fang W; Li Z; Fu X; Cai X
    BMC Med; 2024 Nov; 22(1):522. PubMed ID: 39511550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial.
    Zhao ZR; Liu SL; Zhou T; Chen G; Long H; Su XD; Zhang X; Fu JH; Lin P; Zhang LJ; Rong TH; Wu JD; Li ZC; Su HL; Chen JY; Yang YP; Lin YB; Xi M; Yang H
    Lancet Respir Med; 2024 Dec; 12(12):988-996. PubMed ID: 39305910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial.
    Wu Z; Wu C; Zhao J; Wu C; Peng H; Wang Q; Bai R; Fang X; He H; Shen H; Wu M
    EClinicalMedicine; 2024 May; 71():102579. PubMed ID: 38618203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term efficacy and safety of neoadjuvant Sintilimab combined with chemotherapy for resectable gastroesophageal junction adenocarcinoma.
    Chen L; Zhang S; Ma H; Zhong K; Yang D; Sun J; Liu H; Song R; Cai H
    Langenbecks Arch Surg; 2024 Dec; 410(1):5. PubMed ID: 39666161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.
    Wang X; Kang X; Zhang R; Xue L; Xu J; Zhao X; Ou Q; Yu N; Feng G; Li J; Zheng Z; Chen X; Wang Z; Zheng Q; Li Y; Qin J; Bi N; Li Y
    Clin Cancer Res; 2024 Nov; 30(22):5061-5072. PubMed ID: 39544026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.
    Zhang PF; Zhang WH; Liu XJ; He D; Yang K; Gou HF; Hu JK
    BMJ Open; 2024 Dec; 14(12):e081529. PubMed ID: 39632107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma.
    Makino T; Miyata H; Yasuda T; Kitagawa Y; Muro K; Park JH; Hikichi T; Hasegawa T; Igarashi K; Iguchi M; Masaoka Y; Yano M; Doki Y
    Esophagus; 2024 Oct; 21(4):447-455. PubMed ID: 38990441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.
    Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y
    Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.
    Yu N; Chen X; Li J; Kang X; Wang Z; Zhang R; Qin J; Li Y; Zheng Q; Feng G; Deng L; Zhang T; Wang W; Liu W; Wang J; Feng Q; Lv J; Zhou Z; Xiao Z; Bi N; Li Y; Wang X
    Strahlenther Onkol; 2024 Dec; 200(12):1038-1046. PubMed ID: 39134689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma.
    Yang X; Yin H; Zhang S; Jiang T; Gu J; Jiao H; Wang H; Liang F; Xu S; Fan H; Ding J; Ge D; Wang Q; Yin J; Tan L
    J Thorac Cardiovasc Surg; 2025 Jan; 169(1):289-300.e6. PubMed ID: 38944271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma.
    Li T; Dai Y; Fu X; Cai Q; Ke D; Yao Q; Li J
    BMC Cancer; 2024 Nov; 24(1):1421. PubMed ID: 39558325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.